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Abstract 
Edefuhr, J. 2007.  Use of soy isoflavones as alternative to hormone replacement therapy 
(HRT) for women in menopause. Master thesis. 
 
 
 
The loss of estrogen following menopause can have several effects, including reduction of 
bone mass, menopausal symptoms, such as hot flushes, decreased cognitive function, 
vaginal atrophy, and hypercholesterolemia. Traditional treatment of menopausal symptoms 
using hormone replacement therapy is associated with an increased risk of breast- and 
endometrial cancer, as well as an increased risk of cardiovascular disease. Daidzein, 
genistein and glycitein are isoflavones found in great amounts in soybeans, and soybean 
products. Isoflavones are phytoestrogens, or plant estrogens, that may be classed as natural 
selective estrogen receptor modulators (SERMs). They exert estrogenic effects (e.g. on bone 
and plasma lipids) and antiestrogenic effects or no effect on tissues where estrogen 
stimulation may be undesirable (e.g. breast and endometrium). 
 
 The current evidence indicates that there are few risks and many potential health benefits 
for women in menopause to increase their intakes of isoflavones. The effects of isoflavones 
may be affected by the ability to produce equol. Treating menopausal symptoms via 
increasing intakes of isoflavones may provide an important alternative to the traditional 
hormone replacement therapy. Although long-term intervention studies needs to be done 
before definitive conclusions can be drawn, whether soy isoflavones alone can serve as a 
safe and effective alternative to hormone replacement therapy. 
 
 The main objective of this master thesis was to investigate the effects of isoflavones in 
women during menopause on the menopausal symptoms, bone mass, breast, endometrium, 
and cardiovascular disease risk by reviewing current literature in the area. 
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1. Objectives 
The main objective of this master thesis was to investigate the effects of 
isoflavones in women during menopause on the menopausal symptoms, bone 
mass, breast, endometrium, and cardiovascular disease risk by reviewing current 
literature in the area.  
 
 The specific questions addressed were: 
 
 -  How does isoflavones affect women during menopause? 
 -  How does isoflavones exert its effect?   
-  How much isoflavones is needed to convey their health benefits, and how can 
this be obtained? 
 -  How safe is a diet rich in isoflavones? 
 
 
 
 
2. Introduction 
Hormone replacement therapy (HRT) has traditionally been used for treatment of 
menopausal disorders. However, not all women can, or wish to, take HRT (Warren 
et al., 2002). More and more women rely on phytoestrogens, or plant estrogens, 
such as isoflavones to tailor their menopausal therapy in a “natural” way. 
Isoflavones may be classed as natural selective estrogen receptor modulators 
(SERMs) (Carusi, 2000), that exert selective estrogenic effects (e.g. on bone and 
plasma lipids) and anti-estrogenic effects or no effect on tissues where estrogen 
stimulation may be undesirable (e.g. breast and endometrium) (Nussey & 
Whitehead, 2001). Ideally SERMs would treat such symptoms as hot flushes, 
vaginal dryness, and mood changes, while protecting women from osteoporosis 
and cardiovascular disease, without substantially increasing the risk of endometrial 
cancer (Carusi, 2000).  
 
2.1 Menopause 
The menopause is the cessation of menstruation at the end of a woman’s 
reproductive life. Operationally it is defined as the absence of menstruation for a 
year (Nussey & Whitehead, 2001). The term perimenopause or premenopause is 
defined by the World Health Organization as the two to eight years prior to 
menopause and one year following final menses. Natural menopause is a result 
from the loss of ovarian follicular activity (WHO, 1996). The loss of estrogen 
following menopause has several effects, not only physically but also 
psychologically. Some of the effects are limited to the transition period when a 
woman is adjusting to the loss of her hormones, such as menstrual periods 
becoming irregular. Other may occur first at the actual menopause, but may have 
serious consequences in the long term (Nussey & Whitehead, 2001). Some of the 
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deleterious effects of lowered estrogen levels include reduction of bone mass, 
menopausal symptoms, and hypercholesterolemia (Somekawa et al., 2001). 
Osteoporosis is one of the most common endocrine diseases and occurs when the 
bone resorption exceeds the bone formation. The bone loss is accelerated for 
several years after the withdrawal of estrogens at the menopause (Nussey & 
Whitehead, 2001). Primary menopausal symptoms are considered to be the 
vasomotor symptoms, referring to hot flushes and night sweats. The vasomotor 
symptoms may also be associated with sleep and mood disturbances, as well as 
decreased cognitive function. Other menopausal symptoms are urogenital atrophy, 
urinary tract infections and incontinence, somatic symptoms, sexual dysfunction 
and decreased libido, and loss of skin elasticity (Utian, 2005; Cheung et al., 2004). 
Epidemiologically women appear to be protected against cardiovascular disease by 
their sex hormones (Nussey & Whitehead, 2001), and incidence of cardiovascular 
disease have been shown to increase substantially after menopause (Wroblewski 
Lissin & Cooke, 2000). This adverse effect of menopause has been attributed to 
the metabolic effect of the loss of estrogen increasing the atherogenic potential of 
circulating lipids leading to coronary artery disease and stroke (Nussey & 
Whitehead, 2001). 
 
2.2. Hormone replacement therapy 
Hormone replacement therapy (HRT) refers to a variety of treatments involving 
different estrogens and progestins (Cheung et al., 2004). HRT may be used during 
a short period of time to alleviate menopausal symptoms, such as hot flushes and 
vaginal atrophy (Nussey & Whitehead, 2001; Cancellieri et al., 2007). HRT may 
also be used for several years or more to prevent changes in bone density and 
reduce the risk of cardiovascular disease. However, when HRT is stopped the same 
physiological changes that accompany the untreated menopause still occur, but 
later in life (Nussey & Whitehead, 2001). Even if hormone replacement therapy is 
widely used with evident success in menopausal women, approximately 70% drop 
out after the first year of treatment. Reasons for dropping out were irregular 
bleeding, breast discomfort, nausea, migraine, weight gain, water retention, besides 
the fear of breast cancer (Elkind-Hirsh, 2001). Over the last few years there has 
been a debate about HRT safety particularly with regard to the risk of developing 
breast cancer, but also the increased risk of endometrial cancer (Nussey & 
Whitehead, 2001; Beck et al., 2003). A randomized, double blind placebo-
controlled trial from the Women’s Health Initiative (WHI) showed an increase in 
both cardiovascular disease and breast cancer (Writing group for the Women’s 
Health Initiative investigators, 2002). The study involved 16,608 post-menopausal 
women who were given estrogen plus progestin or a placebo. The study was 
however terminated early as the risk was considered higher than the benefits. After 
an average of 5.2 years follow up, there was a 26% increase in breast cancer, 29% 
increase in coronary heart disease and a 41% in strokes among those who received 
estrogen plus progestins. However a 34% decrease in hip fractures and a 37% 
decrease in colorectal cancers were also reported among the hormone users 
(Writing group for the Women’s Health Initiative investigators, 2002). In the U.S. 
hormone therapy prescriptions have declined as a response to the evidence 
substantiating cardiovascular disease harms and breast cancer risk (Hersh et al., 
2004). Some women may also not be able to treat their menopausal problems with 
HRT as they have absolute contraindications such as undiagnosed vaginal 
bleeding, active thromboembolic disease and active breast or endometrial cancer 
(Nussey and Whitehead, 2001). Concerns about the risks of conventional HRT 
have led increasingly more women and their practitioners to seek alternative 
therapies (Wroblewski Lissin & Cooke, 2000).  
2.3. Isoflavones 
More and more women rely on phytoestrogens, or plant estrogens, such as 
isoflavones to tailor their menopausal therapy in a “natural” way (Carusi, 2000). 
Isoflavones may be classed as natural selective estrogen receptor modulators 
(SERMs) (Carusi, 2000), that exert selective estrogenic effects (e.g. on bone and 
plasma lipids) and anti-estrogenic effects or no effect on tissues where estrogen 
stimulation may be undesirable (e.g. breast and endometrium) (Nussey & 
Whitehead, 2001). Asian people consume 10-100 times more isoflavones than 
Western people (Barnes et al., 1995; Wu et al., 1998), and it has been shown that 
Japanese women experience fewer hot flushes (Lock, 1991), fewer hip fractures 
(Cooper et al., 1992) and a decreased rate of hormone-dependent cancers (Parkin, 
1989) in comparison to American women. Phytoestrogens are diphenolic 
compounds that structurally resemble human estrogens (Hurst, 2002; Setchell & 
Adlercreutz 1988). As seen in Fig. 1. the isoflavone daidzein and its metabolite 
(Section 3.4.) equol are almost identical to endogenous 17β-estradiol. 
 
 
 
 
Figure 1. Similarity of the endogenous estrogen (17b-estradiol) to isoflavones (Equol, 
Daidzein) 
 
The structural similarity of isoflavones to estrogens enables them to bind to 
estrogen receptors and provides them the ability to mildly mimic and in some cases 
act as antagonist to estrogen (Hurst, 2002; Jordan, 1990). When the level of 
estradiol is low, as it is in menopause, isoflavones exert more agonist properties 
and thus mildly mimic endogenous estrogen actions (Setchell & Cassidy, 1999; 
Collins et al., 1997). These effects are also tissue specific (Setchell & Cassidy, 
1999). 
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2.4. Isoflavones and estrogen receptors α and β  
Hormones and signaling molecules control gene expression by binding to nuclear 
receptor proteins. Nuclear receptors act as transcription factors. By binding to 
specific response elements they regulate the expression of target genes (Härd & 
Gustafsson, 1993; Tsai & O’Malley, 1994).  
 
 In the 1960s the existence of a protein responsible for specific binding of 17β-
estradiol in the uterus was recognized (Jensen & Jacobson, 1962). In 1996 a novel 
estrogen receptor was discovered in the rat prostate. It was named estrogen 
receptor β (ER-β) to distinguish it from the previously cloned estrogen receptor α 
(ER-α) (Kuiper et al., 1996). These two known estrogen receptors ER-α and ER-β 
may play different roles in gene regulation (Paech et al., 1997).  
 
 The DNA-binding-domains (DBD) of the two ERs share approximately 97% 
similarity. In the ligand-binding-domain (LDB), the overall amino acid identity is 
59 % see Fig. 2. (Gustafsson, 1999). Those parts of the LDB involved in the actual 
binding of ligand are similar in ER-β and ER-α and show similar binding 
specificities (Kuiper et al., 1997). 
 
 
 
 
Figure 2. Comparison of the amino acid sequences of the two estrogen receptors. The 
separate domains are identified in the ER-α diagram. The numbers in the ER-β diagram 
represent the degree of homology (%) between respective domains in the two receptors 
(Adapted from Gustafsson, 1999). 
 
 
The selective action of estrogens in different tissues may be explained by the 
distribution and ligand binding affinities for ER-α and ER-β (Kuiper et al., 1997; 
Paech et al., 1997). ER-β is found in the brain, bone and vascular epithelia sites 
that are specific targets where classical estrogen replacement therapy is beneficial, 
see Fig. 3. (Setchell & Cassidy, 1999). 
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Figure 3. The anatomical distribution of ER-α and ER-β. (Setchell & Cassidy, 1999) 
 
 
Interaction between hormones and their receptors depends on the number of 
receptors, the concentrations of circulating hormones and the affinity of the 
hormone receptors. The affinity of the hormone receptor is the concentration of 
hormone required to occupy 50% of the receptors. The higher the affinity the 
lower the concentration of hormone is required. The affinity of hormone receptors 
does not generally change and as a result the biological response depends on the 
number of receptors and the concentration of the hormone (Nussey & Whitehead, 
2001). Phytoestrogens exhibit weak estrogenic activity on the order of 10-2–10-3 
that of 17ß-estradiol, but may be present in the body in concentrations 100-fold 
higher than endogenous estrogens, which may explain their biological response 
(Tham et al., 1998) 
 
 The affinities for various compounds and the transcriptional response a given 
compound is able to elicit differ between the two receptor types (Pettersson & 
Gustafsson, 2001). 17β-estradiol binds to ER-α and ER-β with equal affinity, 
whereas soy isoflavones have a preference for binding to ER-β (An et al., 2001). 
However, the maximal transcriptional stimulation by phytoestrogens achieved with 
ER-β is only about half that of ER-α, despite their higher affinity for ER-β 
(Barkhem et al., 1998). Daidzein has been shown to have lower affinity for ER-α 
and ER-β compared with genistein (Kuiper et al., 1998). 
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3. Isoflavones  
3.1. Dietary sources 
In most populations soy is the major source of phytoestrogens such as isoflavones 
(Tham et al., 1998). Traditional soy food products have been consumed for more 
than 1000 years by people throughout Asia. However, it is only for the past 25 
years the Western cultures have begun to add soy food to their diets. Today soy 
foods are available in many types throughout the world. Soy foods can be divided 
into two categories: nonfermented and fermented. Traditional nonfermented 
soyfoods are fresh green soybeans, whole dry soybeans, soy nuts, soy sprouts, 
whole-fat soy flour, soymilk and soymilk products, tofu, okara and yuba. 
Fermented soyfoods are tempeh, miso, soy sauces, natto and fermented tofu and 
soymilk products (Golbitz, 1995).  
 
 Some of these foods have wholeheartedly been adopted by Westerners, whereas 
others have not yet been accepted. Tofu, soymilk, soy sauce, miso and tempeh 
belong to the most popular soy food products in the U.S. The Americans have also 
created a whole new class of “second generation” soyfoods such as tofu hot dogs, 
tofu ice cream, veggie burgers, tempeh burgers, soymilk yoghurt, soymilk cheeses, 
soy flour pancake mix and several other prepared Americanized soyfoods (Golbitz, 
1995).  
3.2. Function in Plants 
Isoflavones are substances that the plant produces to defend itself, also known as 
phytoalexins (Messina et al., 1994). There are also other classes of substances 
apart from the phenolic compounds that work as phytoalexins, such as terpenoids 
and alkaloids (de Bruxelles and Roberts, 2001).  Phytoalexins are produced in 
greater amounts when the plants are stressed. Dehydration, mechanical injury, 
microbial infections and ultraviolet irradiation are some of the known plant 
stressors (Messina et al., 1994). Not only do the isoflavones play important roles 
as defensive compound against microorganisms, but they enjoy a very intricate 
relationship with certain nitrogen-fixing bacteria and actually help the soybean to 
grow (Subramanian et al., 2004; Aoki et al., 2000; Zhang et al., 2000; Messina et 
al., 1994). 
 
 
3.3. Content in soybeans and soy food 
Soybeans contain three types of isoflavones (daidzein, genistein and glycitein) 
found in four chemical forms (aglycons, glucosides, acetylglucosides and 
malonylglucosides) (Kudou et al., 1991): 
 
Aglycons   Glucosides    Acetylglucosides   Malonylglucosides
Daidzein   Daidzin     6’’-O-acetyldaidzin  6’’-O-malonyldaidzin 
Genistein   Genistin    6’’-O-acetylgenistin  6’’-O-malonylgenistin 
Glycitein   Glycitin     6’’-O-acetylglycitin  6’’-O-malonylglycitin 
 Isoflavones accumulate in soybeans during seed development. They are 
synthesized within seed tissues from simple precursors, but transport from 
maternal tissues may also contribute to the accumulation of these natural products 
in seeds (Dhaubhadel et al., 2003). There is considerable variation in the 
phytoestrogen concentrations of different plants. The concentrations of these 
compounds can be influenced by a number of factors including plant species, 
strain, crop year and geographical location (Elridge & Kwolek, 1983; Wang & 
Murphy, 1994a). The mean content of isoflavones in raw soybeans from different 
locations is presented in Table 1.  
 
 
Soybeans from different locations mg isoflavones/100g edible portion 
Brazil 87.63 
Japan 118.51 
Korea 144.99 
Taiwan 59.75 
 
Table 1. The mean content of isoflavones in raw soybeans from different locations (U.S. 
Department of Agriculture, Agricultural Research Service, 2007). 
 
 
 Nearly all isoflavones are found in the soybean hypocotyl with low to moderate 
amounts found in the cotyledon (Fig. 4.). 
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Figure 4. Anatomy of a bean seed. 
 
 
 Traditional processing of soybeans into food does not separate these seed parts 
(Wang & Murphy, 1994b). The glucoside forms genistin and daidzin account for 
95-99% of the total isoflavone content of whole soybeans (Naim et al., 1974). 
Nonfermented soy foods have greater levels of glucosides, whereas fermented soy 
foods contain greater levels of aglycons. The retention and distribution of 
isoflavone isomers in soy foods are affected by the variety of soybean, method of 
processing and addition of other components (Wang & Murphy, 1994b). For 
example soy concentrate can be produced by a water or alcohol wash of soy flakes 
to remove soluble carbohydrates and improve functionality. However alcohol 
washing removes most of the isoflavones (Wang & Murphy, 1994b). 
3.4. Metabolism of isoflavones 
The effects of isoflavones in humans are to a great extent mediated by intestinal 
microflora (Adlercreutz, 2002), and the variation in the effects among individuals 
has been attributed to differences in their metabolism (Rafii et al., 2003) Once they 
have been ingested isoflavones are metabolized into diverse compounds in the 
intestine that might have increased or decreased estrogenic activity (Hwang et al., 
2006; Rafii et al., 2003). Genistin and daidzin, the two most prevalent forms in soy 
foods, are biologically inactive. Once they have been ingested they are cleaved by 
glucosidases to the corresponding aglycones genistein and daidzein (Setchell et al., 
2002). Genistein is further metabolized by intestinal microflora to 
dihydrogenistein, while daidzein is converted either to equol or O-
desmethylangolensin (O-DMA) (Heinonen et al., 1999; Kelly et al., 1993; Setchell 
et al., 2002), equol being more estrogenic than either daidzein or O-DMA 
(Setchell et al., 2002). Steps involved in the absorption and metabolism of 
isoflavones are illustrated in Fig. 5. 
 
Isoflavone 
glucosides 
Isoflavone 
aglycones 
Isoflavone 
metabolites 
Absorption Absorption 
 Genistin 
 Daidzin 
 Genistein 
 Daidzein 
 Dihydrogenistein 
 Equol, O-DMA 
Intestinal 
 
Glucosidases 
Intestinal 
 
Bacterial enzymes 
 
Figure 5. Summary of the absorption and metabolism of isoflavones. 
 
 
 Following absorption, isoflavones undergo hepatic conjugation to glucoronic 
acid or sulphate. They, as well as endogenous steroids, undergo enterohepatic 
circulation whereby they are deconjugated in the intestine and re-absorbed or 
excreted in the faeces (Setchell, 1998; Setchell & Cassidy, 1999). The absorption 
of isoflavones is dose-dependent, meaning that serum and urinary concentrations 
of isoflavones increase in accordance with the amount consumed (Karr et al., 
1997). 
3.4.1. Individual differences 
The effects of dietary isoflavonoids vary among individuals. This has been 
attributed to differences in their metabolism by intestinal bacteria (Rafii et al., 
2003). Equol, metabolite of daidzein, is more estrogenic than both daidzein and O-
DMA (Setchell et al., 2002), and it binds to both human ER forms (ERα- and β), 
has high antioxidant activity, and is relatively stable (Dixon, 2004). Equol is found 
in the urine of 30-40% of individuals who consume isoflavones (Setchell et al., 
2002). The efficacy of soy foods differs depending on the ability of an individual 
to produce equol, and the frequency varies both among individuals and 
 12 
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populations. It was found that the frequency of eqoul producers in vegetarians was 
59%, similar to the reported frequency in Japanese adults consuming soy, which is 
much higher than for non-vegetarian adults (25%), suggesting that dietary 
components other than soy influence equol synthesis by intestinal bacteria 
(Setchell et al., 2006), such as carbohydrate and dietary fiber levels (Slavin et al., 
1998; Lampe et al., 1998). This fact can complicate epidemiological and dietary 
intervention studies (Dixon, 2004). Compared with Western populations, Asian 
populations have a higher eqoul-producer frequency (Song et al., 2006). There are 
also significant interspecies differences in isoflavone metabolism. In one study 
female pigs had an overall metabolic profile closer to woman than to either female 
cynomolgus monkeys or rats, making the pig perhaps a better animal model for 
studying the health effects of isoflavones in nonequol producers (Gu et al., 2006). 
The inability to produce equol in some humans may be due to the fact that they are 
host to a different population of intestinal microorganisms (Setchell et al., 2002). 
There might be ways to convert a nonequol-producer into a producer through 
administering a mixed microbial culture which have shown to efficiently transform 
daidzein to equol. In one study it was found that administration of eqoul-producing 
bacteria to a dynamic in vitro model of the gastrointestinal tract, inoculated with a 
nonequol-producing fecal sample, resulted in the formation of equol in the distal 
colon parts. The effect also maintained beyond the period of inoculum 
administration. However further studies and experiments with in vivo models are 
necessary to explore the efficacy and safety of supplementation with equol-
producing bacteria (Decroos et al., 2006). 
 
 One study found that isoflavone metabolism and disposition were affected by the 
duration of soy ingestion and by sex (Lu & Anderson, 1998). They found that 
some women who initially were unable to metabolize daidzein to equol, developed 
this ability during chronic soy ingestion, but this was however not noticed in men. 
Thus, in women, ability to metabolize daidzein to equol can be increased by 
prolonged ingestion (Lu & Anderson, 1998).  
 
 There are conflicting results in the literature on the bioavailability of isoflavones 
when consumed in the aglycone form compared with when consumed in the 
glucoside form. Izumi et al., 2000, reported that the bioavailability of both 
genistein and daidzein from the aglycone form was significantly higher and faster 
than from the glucoside form when consumed by 8 Japanese volunteers. However, 
a study with only Americans with typical American dietary habits showed no 
significant difference when isoflavones were consumed as either the aglycone or 
glucoside form (Zubik & Meydani, 2003). Yet another study demonstrated that the 
overall bioavailability may increase if the compounds are ingested as their 
glucosides rather than as aglycones (Setchell et al., 2001). The differences in 
reported bioavailability of isoflavones may be accounted for by differing intestinal 
microfloral populations between Japanese and American women, if the isoflavones 
were ingested together with food and a potentially different food matrix (Zubik & 
Meydani, 2003). 
 
 When equal amounts of genistein and daidzein are consumed, genistein attains 
higher plasma concentrations than daidzein. Daidzein is to a larger extent 
distributed in the whole body compared with genistein. Genistein have greater 
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systemic bioavailability than daidzein. These differences in pharmacokinetics and 
metabolism may have implications for clinical studies, while assumptions cannot 
be made that all isoflavones are comparable in their pharmacokinetics and 
bioavailability (Setchell et al., 2001).  
 
 Bioavailability of daidzein can be affected by the ability to produce equol 
(Vergne et al., 2007). Vergne et al., 2007 showed that equol producers excreted 
significantly less daidzein than equol non-producers. The difference disappeared 
when equol excretion was added to daidzein excretion in equol producers. 
 
 
 
4. Potential clinical effects of isoflavones in 
menopause 
4.1. Cardiovascular disease 
Coronary artery disease (CAD) is the most common cause of mortality for women 
and increases dramatically after menopause (Wroblewski Lissin & Cooke, 2000). 
A high blood concentration of low-density lipoprotein (LDL) is an established risk 
factor for cardiovascular disease (Ballantyne, 1998). Women have more favorable 
lipoprotein profiles than men starting in adolescence. At the time of menopause, 
however, adverse changes in lipoprotein profiles occur, including increases in total 
and LDL cholesterol, decrease in high-density lipoprotein (HDL), and shift in LDL 
particle size toward smaller, denser particles. These adverse changes have been 
attributed to the changes in estrogen levels that occur at the time of menopause 
(Bittner, 2002). This theory is further supported by the increased incidence of 
cardiovascular events in younger, surgically postmenopausal women (Wroblewski 
Lissin & Cooke, 2000).  
 
 Epidemiologic data have shown that women ingesting high amounts of 
phytoestrogens from soy products have less cardiovascular disease, than those 
eating Western diets (Wroblewski Lissin & Cooke, 2000). Soy, and especially the 
isoflavones contained in soy, has been suggested to improve lipoprotein levels, 
thus reducing the risk of CAD. However, this hypothesis is not uniformly accepted 
(Dewell et al., 2006). A pivotal paper in this field is an often cited meta-analysis of 
38 controlled clinical trials of soy consumption in humans. Improvements in total 
cholesterol by 9.3% and LDL by 12.9%, as well as a decrease in triglyceride levels 
of 10.5% were revealed. The average intake of soy was 47g/day in these trials. The 
extent of reduction was dependent upon the initial serum cholesterol 
concentrations. In subjects with moderate hypercholesterolemia, a decrease in total 
cholesterol of 7.4% was observed, whereas subjects with severe 
hypercholesterolemia achieved a decline of 19.6% (Anderson et al., 1995). 
However, according to recent reviewers (Sacks et al., 2006; Dewell et al., 2006) 
this meta-analysis was limited by the quality of the studies. Dewell et al., 2006 and 
Lichenstein et al., 2002, noted that 77% of the studies in this meta-analysis had 
95% confidence intervals that encompassed zero and hence the findings should be 
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viewed with caution. In the majority of 22 randomized trials, isolated soy protein 
with isoflavones decreased LDL cholesterol concentrations. The average effect 
was approximately 3%, as compared with milk or other proteins. The reduction is 
considered small relative to the large amount of soy protein tested in these studies, 
averaging 50g, which is about half the usual total daily protein intake in the US. 
Most recent studies favor soy protein rather than soy isoflavones as the responsible 
nutrient although it cannot be ruled out that another component in soybeans could 
be the active factor (Sacks et al., 2006). Dewell et al., 2006, noted that “the 
changes reported in studies using purified isoflavones supplements, although not 
statistically significant, are quantitatively similar to those observed in the soy 
protein studies”. Many studies during the past 10 years have not confirmed earlier 
research indicating that soy protein has clinically important favorable effects on 
LDL cholesterol and other cardiovascular disease risk factors, as compared with 
other proteins. However, because of soy products high content of polyunsaturated 
fats, fiber, vitamins, and minerals and low content of saturated fat it still should be 
beneficial to cardiovascular and overall health (Sacks et al., 2006).  
 
 Dietary isoflavones have also been attributed cardioprotective benefits beside the 
reduction in LDL cholesterol, including an inhibition of pro-inflammatory 
cytokines, cell adhesion proteins and inducible nitric oxide production, potential 
reduction in the susceptibility of the LDL particle to oxidation, inhibition of 
platelet aggregation and an improvement in vascular reactivity. Increasing number 
of studies reveal a significant impact of genetic variation on changes in 
cardiovascular risk factors in response to dietary intervention. This might explain 
some of the differences in the current literature concerning isoflavones and 
cardiovascular health (Rimbach et al., 2007). 
4.2. Breast cancer 
At the beginning of the 1980s it was proposed that isoflavonoids may prevent 
breast cancer. This was the starting point of numerous epidemiological, 
experimental, case-control and prospective studies investigating the hypothesis 
(Adlercreutz, 2002). Epidemiological observations show that Asian women have 
significantly lower risk of breast cancer compared with Western women (Parkin, 
1989). Studies assessing cancer risk and diet have provided support for the theory 
that high intake of isoflavone-rich soy contributes to this risk difference. The 
findings of these studies showed significant inverse associations between breast 
cancer and soy isoflavones, both in relation to their consumption and their urinary 
excretion (Duncan et al., 2003). Observations that Asian women who emigrate to 
the U.S. and adopt Western diet lose their lower risk of breast cancer further 
support the hypothesis that isoflavones may prevent breast cancer (Ziegler et al., 
1993). In the Asian countries the diets are also low in fat and red meat and are 
often rich in fish, elements that have independently been linked to a decreased 
cancer risk (Adlercreutz, 2002).  
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4.2.1. Mechanisms 
Some epidemiological evidence suggests that the chemoprotectant effects of 
isoflavones are dependent on lifelong exposure from childhood (Limer and Speirs, 
2004). Studies in rodents have shown that the favourable effect of an isoflavone-
rich diet on breast-cancer risk may only be significant if consumption takes place 
before puberty or during adolescence (Lamartiniere, 2000). Lamartiniere, 2000, 
concludes that “genistein at physiological concentrations enhances cell 
differentiation, resulting in programming of the mammary gland, with no observed 
toxicity to the reproductive tract”. He also concluded that “reduced EGFR 
(epidermal growth factor receptor) expression at the time of carcinogen exposure 
may account for genistein programming against mammary cancer”.  
 
 Soy isoflavones may reduce the risk of breast-cancer by affecting endogenous 
sex-hormone concentrations and the menstrual cycle (Adlercreutz, 2002). Studies 
have shown that phytoestrogens stimulate the production of SHBG (sex-hormone 
binding globulin) in liver cells (Adlercreutz et al., 1987). A low lifetime exposure 
to estrogen is associated with a reduced breast-cancer risk (Limer and Speirs, 
2004) thus an increase in SHBG levels, leading to lower free-sex-hormone 
concentrations and longer menstrual cycles would lower the risk of breast-cancer 
(Adlercreutz, 2002).  
 
 Equol production in the gut has been associated with a lower risk of breast-
cancer (Duncan et al., 2000). People that produce high concentrations of equol 
have an increased ratio of 2-hydroxyestrone to 16α-hydroxyestrone in their urine. 
High urinary excretion of 2-hydroxyestrone relative to 16α-hydroxyestrone is 
thought to decrease breast-cancer risk (Atkinson et al., 2003). Equol producers 
also show higher concentrations of SHBG than non-equol producers (Duncan et 
al., 2000). 
 
 Genistein have been shown by both in vitro and in vivo studies to be a promising 
agent for cancer chemoprevention and/or treatment. Genistein has been shown to 
inhibit the growth of cancer cells through the modulation of genes that are related 
to the homeostatic control of cell cycle and apoptosis (programmed cell death). 
Genistein inhibits the activation of the nuclear transcription factor NF-κB and Akt 
signaling pathway, both of which are known to uphold a balance between cell 
survival and apoptosis (Sarkar and Li, 2002). NF-κB is needed for tumor cell 
proliferation, invasion, and angiogenisis, and tumor cells have been found to 
constitutively express the activated form of NF-κB. Inhibition of NF-κB is 
therefore likely to prevent tumor metastasis (Bharti and Aggarwal, 2002). Akt, 
which is also known as protein kinase B, represents a subfamily of the 
serine/threonine kinase. The activation of the Akt pathway plays a pivotal role in 
malignant transformation and chemoresistance by inducing cell survival, growth, 
migration, and angiogenesis. Inhibition of Akt kinase results in suppression of cell 
growth and induction of apoptosis in human cancer cells that have constitutively 
activated Akt (Yang et al., 2004). Genistein is also known for its anti-oxidant 
property, which targets estrogen and androgen-mediated signaling pathway in the 
process of carcinogenesis. Genistein have also been found to be a potent inhibitor 
of angiogenesis and metastasis (Sarkar and Li, 2002).  
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4.2.2. Soy for breast cancer patients, is it safe? 
Tamoxifen is a selective estrogen receptor modulator (SERM) used clinically in 
the adjuvant treatment of estrogen-dependent breast cancer. Individuals at high 
risk of developing breast cancer are also administered tamoxifen as a prophylactic. 
Therapies using tamoxifen is associated with menopausal symptoms such as hot 
flushes, joint pain, sleep disorders and depression, which may be reduced by the 
use of HRT. However long-term use of HRT for breast cancer patients is 
discouraged as HRT is associated with an increased risk for mammary 
carcinogenesis (Limer and Speirs, 2004). Soy isoflavone supplements may be used 
as a natural alternative to alleviate the tamoxifen-induced menopausal symptoms 
(Wuttke et al., 2002). The ingestion of dietary phytoestrogens by breast cancers 
patients and survivors is, however, controversial (Messina and Loprinzi, 2001). 
Concerns over possible detrimental effects of soy in breast cancer patients have 
arisen because of the estrogen-like effects of isoflavones. Genistein have been 
shown to have a biphasic effect on the growth of MCF-7 cells (an estrogen 
receptor-positive cell line), stimulating proliferation at low concentrations but 
inhibiting it at high concentrations. Both genistein and soy protein stimulate tumor 
growth in a dose-dependent manner in ovariectomized athymic mice implanted 
with MCF-7 cells. In intact mice fed estrogen, however, genistein inhibits tumor 
growth. These studies might suggest that in a low-estrogen environment, perhaps 
as exist in a postmenopausal women (and possibly breast cancer patients as a result 
of chemotherapy-induced menopause), genistein is estrogenic and has a 
proliferative effect on breast tissue. In a high estrogen environment such as exists 
in a premenopausal woman genistein has an antiproliferative and possibly 
antiestrogenic effect. Two studies in premenopausal women suggest that soy exert 
estrogenic-like effects on breast tissue. However, two other studies, both 1 year 
long, indicated that isoflavone supplements do not affect breast tissue density in 
premenopausal women and may decrease density in postmenopausal women 
(Messina and Loprinzi, 2001). Messina and Loprinzi, 2001, conclude in their 
review that “the data are not impressive that the adult consumption of soy affects 
the risk of developing breast cancer or that soy consumption affects the survival of 
breast cancer patients. Consequently, if breast cancer patients enjoy soy products, 
it seems reasonable for them to continue to use them”.  
4.3. Endometrial cancer 
Over the last few years there has been a debate about HRT safety particularly with 
regard to the risk of developing breast cancer, but also the increased risk of 
endometrial cancer (Nussey & Whitehead, 2001; Beck, 2003). 
 
 Some studies have investigated the effect of isoflavones on the endometrium. 
Isoflavones have had no effect on the endometrium thickness when given alone 
(Upmalis et al., 2000; Penotti et al., 2003), or in combination with soy protein 
(Han et al., 2002). Neither have isoflavones had an estrogenic effect on 
endometrial histology (Duncan et al., 1999; Balk et al., 2002).  
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 One randomized, double-blind, placebo-controlled study determining the effects 
of 5 years treatment with soy isoflavones on histological characteristics of 
endometrium in postmenopausal women suggested that long-term treatment with 
soy isoflavones was associated with an increased occurrence of endometrial 
hyperplasia (Unfer et al., 2004). However, most isoflavone supplements are given 
at a dosage of no more than 80mg/day, and in this study the isoflavones was 
administered at a higher dosage of 150mg/day (Unfer et al., 2004). 
4.4. Osteoporosis 
The continual loss of bone mass when you get old is a natural process of aging. 
Osteoporotic fractures are more common among women than men, due to their 
lower peak bone mass. But also, the abrupt decrease in estrogen secretion in 
postmenopausal women accelerates bone loss (Tham et al., 1998).  
 
 Both bone resorption and bone formation increase during menopause (Heikkinen 
et al., 1997). When bone resorption exceeds its formation osteoporosis takes place 
(Nussey and Whitehead, 2001). Two different cell lines are involved in bone 
remodeling. Osteoblasts are responsible for bone formation, and it responds to 
changes in the activity of osteoclasts, the bone resorbing cells. Maintaining bone 
homeostasis involves many hormones, growth factors, and cytokines that play 
regulatory roles. Estrogen in particular suppresses osteoclast activity and thereby 
prevents bone resorption (Setchell and Lydeking-Olsen, 2003). 
 
 The incidence of hip fractures is significantly lower among Asian women 
relative to Caucasian women (Lauderdale et al., 1997). Differences in bone 
mineral density (BMD) and fracture rates among Asian and Western people are 
probably due to multiple factors. Studies on cultured bone cells and rat models of 
postmenopausal osteoporosis support a significant bone-sparing effect of the soy 
isoflavones genistein and daidzein. However, reported findings on phytoestrogens 
and bone in human studies have given variable results. This might be explained by 
differences in the ability to produce equol (Setchell and Lydeking-Olsen, 2003). In 
a study by Lydeking-Olsen et al., 2004, the group of women able to produce equol 
showed an increase of 2.4% in lumber spine BMD (p<1 compared with control 
group), while there were no significant change in BMD in the “non-equol” 
producer group.  
4.4.1. Mechanisms 
The mechanism of action for isoflavones is still elusive. However, from the many 
lines of evidence it is evident that there are probably multiple pathways, genomic 
and nongenomic, that help conserve the integrity and activity of the two cell lines 
(osteoblasts, and osteoclasts) to maintain stable bone mass in adults (Setchell and 
Lydeking-Olsen, 2003).  
 
 Estrogen receptors ER-β (Onoe et al., 1997) and ER-α (Bodine et al., 1998) are 
found in human osteoblasts. The expression of ER-β is greatly increased during 
bone mineralization (Arts et al., 1997), which is particularly important to the 
potential hormonal effects of phytoestrogen, considering that compounds such as 
genistein show much higher affinity for ER-β than ER-α. (An et al., 2001). 
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 Stimulatory effects on protein synthesis and on alkaline phosphatase release by 
various types of osteoblasts cells in vitro have been reported for both daidzein and 
genistein. It has been suggested that daidzein and genistein influence 
transcriptional or translational events to convey these effects (Setchell and 
Lydeking-Olsen, 2003). Genistein have been found to stimulate the production of 
osteoprotegerin, a factor that prevents bone resorption, providing a further 
mechanism for the bone-sparing effects of soy isoflavones (Viereck et al., 2002). 
 
 Estrogen receptors seem to not be present in the nucleus of osteoclasts cell. 
Osteoblast and osteoclast activities are coupled, but the action of isoflavones on 
the osteoclasts could also be independent of their effects on osteoblasts. There are 
a number of possible mechanisms by which genistein and daidzein can suppress 
osteoclast activity by means of apoptosis, activation of protein tyrosine 
phosphatase, inhibition of cytokines, changes in intracellular Ca2+, and membrane 
depolarization (Setchell and Lydeking-Olsen, 2003). 
 
4.5. Cognitive function 
At menopause the depletion of estrogen may be associated with increased risk of 
neurodegenerative diseases (Dixon, 2004). Estrogen is thought to be 
neuroprotective (Warren et al., 2002) and estrogen treatment has been found to 
improve memory in menopausal women (File et al., 2001). Researchers have 
begun to investigate the effects of isoflavones on the brain (warren et al., 2002). In 
a study examining the effects of supervised high versus low soy diets on attention, 
memory and frontal lobe function in young healthy adults of both sexes, both sexes 
improved memory within 10 weeks (File et al., 2001). 12 weeks of consumption of 
a supplement containing soy isoflavones showed significant cognitive 
improvements in postmenopausal women (Duffy et al., 2003). Studies in rodents 
on brains structure, learning, memory and anxiety has led to the conclusion that 
high consumption of dietary isoflavones over a relatively short time period can 
significantly alter the volume of sexually dimorphic brain regions, increase 
anxiety, and improve learning and visual-spatial memory in females but not in 
males (Lephart et al., 2002). Isoflavones are suggested to prevent degeneration of 
the central nervous system and the development of Alzheimer's disease in 
menopausal women (Kim et al., 2000). Linford and Dorsa, 2002, demonstrated 
that genistein and 17β-estradiol have comparable anti-apoptotic properties in 
primary cortical neurons and that these properties are mediated through estrogen 
receptors.  
 
4.6. Vasomotor symptoms 
Vasomotor symptoms such as hot flushes, night sweats, palpitations and insomnia 
are often associated with menopause (Soliman, 2005). The potential for 
phytoestrogens to alleviate menopausal hot flushes is an area of active research 
(Duncan et al., 2003). Asian women have considerably fewer menopausal 
symptoms than Western women, and it has been hypothesized that this difference 
is due to their high intake of isoflavones (Adlercreutz et al., 1992). A recent meta-
analysis of 17 randomized, controlled, parallel group studies that had compared 
isoflavones therapy (using either soy products or red clover products) to a non-
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isoflavone, non estrogenic comparator, suggest that isoflavone supplementation 
may produce a slight to modest reduction in the number of daily flushes in 
menopausal women and that the benefit may be more apparent in women 
experiencing a high number of flushes (Howes et al., 2006). Numerous 
intervention studies using isoflavone extract have showed inconsistent results, with 
some reporting significantly fewer hot flushes, whereas others report no significant 
effects secondary to an apparent placebo effect (Duncan et al., 2003). A large 
number of clinical trials have reported a decrease in hot flushes in women treated 
with soy protein, however many of these trials fail to prove that soy is superior to 
placebo (Kang et al., 2002). In a community-based study the incidence of hot 
flushes was inversely related both to the amount of soy foods consumed and the 
daily intake of isoflavones; thus, there is indirect evidence for a role for 
isoflavones (Nagata et al., 2001). In a study of 180 Japanese women given a 
standardized questionnaire to evaluate the severity of menopausal symptoms only 
5% reported symptoms of hot flushes (Uchiyama et al., 2001). The daily 
isoflavone intake from soy foods was calculated to be 22±14mg (Uchiyama et al., 
2001), which is much lower dose than doses used in clinical studies of isoflavones 
(Setchell et al., 2002).  In the study of Uchiyama et al., 2001, 53.5% of the group 
was found to be equol-producers on the basis of their urinary equol excretion. All 
of the equol-producers recorded the least severe symptoms assessed by a 
simplified menopausal index score (Uchiyama et al., 2001). Equol-producers may 
therefore gain the most benefit from soy isoflavones for relief of hot flushes. 
Furthermore, not all clinical trials on soy isoflavones stratify women according to 
eqoul status. This might explain why some studies fail to show isoflavones 
effectiveness on hot flushes (Setchell et al., 2002). 
 
 The mechanism by which isoflavones may ease vasomotor symptoms, like hot 
flushes, is by acting as weak estrogen agonists. In a low-estrogen environment, as 
in a postmenopausal woman, isoflavones will exhibit their most potent estrogenic 
effects (Carusi, 2000). 
 
4.7. Vaginal atrophy 
The lower levels of estradiol during menopause can cause vaginal atrophy; the 
vaginal mucosa becomes thinner and dry. The symptoms of vaginal atrophy 
include dryness, burning, itching and painful sexual intercourses. The vaginal 
epithelium may become inflamed, which contribute to urinary symptoms such as 
frequency, urgency, painful urination, incontinence, and/or recurrent infections 
(Castelo-Branco et al., 2005). In a randomized clinical trial analyzing the effects of 
a 6-month soy-rich diet on the vaginal cell maturation on 187 postmenopausal 
asymptomatic women, the maturation value score increased significantly in the diet 
and HRT group but not in the control group (Chiechi et al., 2003). Chiechi et al., 
2003, conclude in this study that a diet rich in soy effectively increase the 
maturation indices of vaginal cells, and that phytoestrogen rich foods should be 
considered during preventive interventions against vaginal atrophy. However, 
another randomized, cross-over trial with two 12-week diet periods could not 
confirm that a soy-rich diet relieves the urogenital symptoms or restore the vaginal 
epithelium or improve the vaginal health in perimenopausal or postmenopausal 
Thai women (Manonai et al., 2006). 
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5. Amounts of isoflavones needed 
The amount of isoflavones needed to exert beneficial effects may vary according 
to the disease in question. Also, the amount of isoflavones needed for health 
benefits when consumed over a life-time might possibly be lower than that needed 
to produce benefits in short-term clinical trials. Most clinical trials use ≥40-90mg 
isoflavones/day. Amounts within this range have produced several beneficial 
effects (Messina, 2004). Intake recommendation of soy protein is 15g (with a 
range of 10-25g) and 50mg (aglycone weight) isoflavones (range of 30-
100mg)/day. Intakes of 15g soy proteins result in consuming approximately 50mg 
isoflavones. These amounts of soy protein and soy isoflavones approximately 
correspond to two servings of traditional soy food. These amounts are also likely 
to be efficacious for those diseases for which soy is proven to be beneficial, and 
there is little reason to think that these intake levels will be associated with any 
adverse effects (Messina, 2002). 
5.1. Soy foods 
Asian populations widely consume isoflavones predominantly in the form of soy. 
Soy foods typically contain 1 to 2 mg genistein/g protein, and Asians consume 20 
to 80 mg of genistein per day in the usual diet. The average American consumes 
only 1 to 3 mg of genistein per day (Barnes et al., 1995). The concentration of 
isoflavones in soy foods and soybeans can vary and are dependent on the soybean 
and processing conditions used to produce a particular food product (Song et al., 
1998). There are also a lot of processed and fast foods with soy additives (e.g. 
isolated soy protein, soy protein concentrate, soy flour, and hydrolyzed soy 
protein, which contain significant levels of isoflavones. These products can 
provide an important source of isoflavones in the diet if consumed regularly 
(Umphress et al., 2005). The mean content of isoflavones in different soy foods are 
presented in Table 2.  
5.2. Supplements 
There is a wide array of isoflavone formulations derived from soy or clover on the 
market today. These commercial isoflavone supplements may make a significant 
contribution to total isoflavone intakes in the West. These supplements usually 
vary in their total isoflavone content, the ratio of individual isoflavones and the 
chemical forms (glycosides vs. aglycone) in which they are present. Furthermore 
the isoflavone content can differ significantly from what manufacturers claim and 
the analysed composition (Rimbach et al., 2007). Setchell and coworkers analyzed 
the composition of 33 commercially-available isoflavone supplements, and found 
that there were in some cases considerable discrepancies between the stated and 
analysed isoflavone concentrations (Setchell et al., 2001). 
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Soy foods mg isoflavones/100g edible portion 
Instant beverage, soy, powder, not reconstituted 109.51 
Miso 42.55 
Miso soup mix, dry 60.39 
Natto (soybeans, boiled and fermented) 58.93 
Soy cheese, unspecified 31.32 
Soy cheese, cheddar 7.15 
Soy cheese, mozzarella 7.70 
Soy cheese, parmesan 6.40 
Soy drink 7.01 
Soy fiber 44.43 
Soy flour (textured) 148.61 
Soy flour, defatted 131.19 
Soy flour, full-fat, raw 177.89 
Soy flour, full-fat, roasted 208.95 
Soy hot dog, frozen, unprepared 15.00 
Soy meal, defatted, raw 125.82 
Soymilk, fluid 9.65 
Soymilk, iced 4.71 
Soymilk skin or film, cooked 50.70 
Soymilk skin or film, raw 193.88 
Soy noodles, flat 8.50 
Soy paste 31.52 
Soy protein concentrate, aqueous washed 102.07 
Soy protein concentrate, produced by alcohol 
extraction 
12.47 
Soy protein isolate 97.43 
Soy sauce made from hydrolyzed vegetable protein 0.10 
Soy sauce made from soy and wheat (shoyu) 1.64 
Soybean chips 54.16 
Soybean curd cheese 28.20 
Soybean, curd, fermented 39.00 
Soybeans, flakes, defatted 125.82 
Soybeans, flakes, full-fat 128.99 
Soybeans, green, mature seeds, raw 151.17 
Soybeans, mature cooked, boiled, without salt 54.66 
Soybeans, mature seeds, dry roasted (includes soy 
nuts) 
176.94 
Tempeh 43.52 
Tempeh burger 29.00 
Tempeh, cooked 53.00 
Tofu 13.51-67.49 
Tofu, yogurt 16.30 
 
Table 2. The mean content of isoflavones in different soy foods (U.S. Department of 
Agriculture, Agricultural Research Service, 2007). 
 23 
5.3. Soy food or isoflavone supplements? Is it safe? 
The absorption of isoflavones from food may be saturable, and it may be more 
difficult to attain supraphysiological levels of isoflavones from food than from 
supplements (Setchell, 2000). With supplementation, there are dangers of 
overdosing (Setchell et al., 2001). Setchell and coworkers found in their 
composition analysis of 33 commercially-available isoflavone supplements 
numerous compounds that they could not identify, and nothing is known about 
these components of these mixtures (Setchell et al., 2001). 
 
 What is critical to the biological efficacy and safety of isoflavones is a thorough 
understanding of their bioavailability from different soy foods. Still to be 
elucidated is whether the pharmacokinetic profile following ingestion of a defined 
dose is influenced by the food matrix in which the isoflavone is given or by the 
processing method used (de Pascual-Teresa et al., 2006), if it varies among 
individuals or whether it is influenced by age (Setchell et al., 2003). The 
information on the pharmacokinetic behavior of isoflavones when ingested at 
levels that far exceed normal dietary intakes is insufficient and remains to be 
elucidated (Setchell et al., 2003). The dose promoted for supplementation, and in 
some cases, fortified functional foods are higher and far in excess of usual dietary 
intakes of Asians (Setchell et al., 2001; Setchell et al., 2003), and there is a 
potential risk for long-term negative effects (Setchell et al., 2003). High levels of 
isoflavones fed to animals have resulted in deleterious effects, and it is not 
impossible that adverse effects also could occur in humans as a result of excessive 
intakes (Setchell et al., 2001).  
 
 The data from the study of Setchell et al., 2003, support the concept that the 
bioavailability of isoflavones from a soy food matrix is nonlinear, with increasing 
doses of intake in the range typically consumed by people living in Asia. The 
serum half life (t1/2) of daidzein and genistein are on the order of 8-10h (Setchell 
et al., 2003). Multiple intakes of soy foods throughout the day are more likely to 
achieve steady-state serum levels, and whether this would give better results in 
dietary interventions studies is not known (Setchell el al., 2003). However Setchell 
et al., 2003, contend on the basis of analogy to many drugs with similar 
pharmacokinetics, “that a portfolio of soy foods that can be eaten throughout the 
day is likely to be more effective than once a day intake”. Setchell et al., 2003, 
also conclude from their data that there is no advantage of ingesting large doses of 
soy isoflavones in soy foods, given the curvilinear relationship between 
bioavailability and intake. 
 
6. Discussion and Conclusions 
The current evidence indicates that there are few risks and many potential health 
benefits for women in menopause to increase their intakes of soy foods, which are 
good sources of isoflavones. Treating menopausal symptoms via increasing intakes 
of isoflavones may provide an important alternative to the traditional hormone 
replacement therapy. Although long-term intervention studies needs to be done 
before definitive conclusions can be drawn, whether soy alone can serve as a safe 
and effective alternative to hormone replacement therapy. Traditional hormone 
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replacement therapy may involve increased risks of developing breast or 
endometrial cancer. The current data on the adult consumption of soy concerning 
development of breast cancer is not impressive enough to discourage women from 
increasing their intake of isoflavones during menopause. Although some studies 
have shown genistein to have proliferative effects on breast tissue when present in 
a low estrogen environment, such as may exist in a menopausal woman, other 
studies indicate that isoflavones do not affect breast tissue density in 
premenopausal women and may decrease breast tissue density in postmenopausal 
women (Messina and Loprinzi, 2001). However more research on the effects of 
isoflavones on the breast is needed. There seem to be no effect of isoflavones on 
the endometrial thickness, although excessive intakes may be associated with an 
increased risk of endometrial hyperplasia. In the randomized, double blind 
placebo-controlled trial done by the Women’s Health Initiative, there was an 
increase in cardiovascular disease in menopausal women given hormone 
replacement therapy (Writing group for the Women’s Health Initiative 
investigators, 2002). Isoflavones and soy protein may, however, have beneficial 
effects on the cardiovascular health by improving lipoprotein profiles, and thus 
reducing the risk of coronary artery disease. The high content of polyunsaturated 
fats, fiber, vitamins, and minerals and low content of saturated fat in soy products 
may also play a crucial role in the beneficial effects on the cardiovascular system. 
Soy isoflavones have been shown to significantly improve cognitive functions in 
postmenopausal women, and it has been suggested to prevent degeneration of the 
central nervous system and the development of Alzheimer’s disease. The effect of 
isoflavones on the vasomotor symptoms are in some cases modest and sometimes 
no better than placebo, however the benefit of isoflavones may be more apparent 
in women experiencing a high number of flushes. Furthermore, isoflavones may be 
preventive against vaginal atrophy.  
 
 The clinical effectiveness of soy protein in cardiovascular, bone and menopausal 
health may be a function of the ability to produce equol. Equol, with its higher 
affinity to estrogen receptors, might be more efficient in preventing diseases and 
treat menopausal symptoms. The variance in results from clinical trials might be 
explained by the fact that not all nutritionists/scientists distinguish between 
subjects that are equol-producers from those who are not. It has been shown that 
equol concentrations are higher in people who have diets containing a lot of plant 
proteins, carbohydrates, and fibre, compared with to those who have a high-fat diet 
(Adlercreutz, 2002). Therefore, one may conclude that soy isoflavones would be 
more efficacious when ingested in the form of soy food, compared to 
supplementing isoflavones to a high-fat diet. Also, when supplementing with 
isoflavones tablets, there is always the risk of overdosing. Setchell et al., 2001, 
found numerous compounds in commercially available isoflavones supplements 
that they could not identify, which might further support the ingestion of 
isoflavones in the form of soy food rather than as supplements. An intake of 15g 
soy protein, resulting in approximately 50mg isoflavones, may be enough to 
convey the health benefits. This corresponds to approximately two servings of 
traditional soy food.
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 Isoflavones exert some of their effects by binding to estrogen receptors and by 
acting as antioxidants. The exact mechanisms by which isoflavones exerts its 
benefits are still a major challenge for nutritionists and scientists. How the 
bioavailability varies among individuals, whether it is influenced by age, gender, 
or what the effects are of ingesting levels that far exceed normal dietary intakes 
remains to be elucidated. 
 
 
 
 
7. Glossary 
Apoptosis: Cell death as a result of activation of an intracellular ”suicide” 
programme.  
Angiogenesis: Development of new blood vessels by sprouting from pre-existing 
vessels.  
Asymptomatic: Having no symptoms, whether disease is present or not.  
Atherogenic: Initiating, increasing, or accelerating atherogenesis. 
Atherogenisis: Formation of atheromatous deposits, especially on the innermost 
layer of arterial walls. 
Athymic mice: A laboratory mouse lacking a thymus gland. Athymic mice have 
no T cells and useful in research because they do not reject tumor or other cells 
transplanted from mice, humans or other species. 
Atrophy: Is a general physiological process of reabsorption and breakdown of 
tissues, involving apoptosis on a cellular level.  
Colorectal cancer: Also called colon cancer or bowel cancer, includes cancerous 
growths in the colon, rectum and appendix. 
Contraindication: A condition or factor that increases the risks involved in using 
a particular drug, carrying out a medical procedure or engaging in a particular 
activity. 
Cytokine: Any protein or polypeptide produced by a cell and which affects the 
growth or differentiation of the same or another cell. The term usually excludes 
endocrine hormones.  
Endometrial hyperplasia: Endometrial hyperplasia is a condition that occurs 
when the lining of the uterus (endometrium) grows too much. It is a benign (not 
cancer) condition. 
Endometrium: The inner membrane of the mammalian uterus. 
Enterohepatic circulation: Refers to the circulation of bile from the liver, where 
it is produced, to the small intestine, where it aids in digestion of fats and other 
substances, back to the liver. 
Epithelium: Sheet of cells tightly bound together, lining all external surfaces and 
internal surfaces continuous with the external environment in multicellular 
animals. 
Fermentation: Anaerobic breakdown of carbohydrates by living cells, esp. by 
microorgansims, often with the production of heat and waste gases. 
Half life: Time required for the disappearance of half the original quantity of a 
given substance, e.g. from the circulation, assuming that the substance 
disappears at a regular rate.  
Homeostasis: (1) Maintenance of the constancy of internal environment of the 
body or part of body; (2) maintenance of equilibrium between organism and 
environment; the balance of nature. 
Homology: Resemblance by virtue of common descent. It refers to structures, 
DNA sequences and behaviours.  
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Hypercholesterolemia: (literally: high blood cholesterol) is the presence of high 
levels of cholesterol in the blood. It is not a disease but a metabolic derangement 
that can be secondary to many diseases and can contribute to many forms of 
disease, most notably cardiovascular disease. 
Hyperplasia: (1) Excessive development due to an increase in the number of cells; 
(2) an abnormal increase in cell proliferation.  
Metastasis: (1) A change in state, position, form or function; (2) the migration of 
cancer cells to colonize tissues and organs other than those in which they 
originated; (3) a secondary tumour caused by migration of cancer cells to 
another tissue.  
Mucosa: The wall of tubular structures such as gut, respiratory tract, urinary and 
genital tracts, which consists of several distinct layers of tissue.  
Nitric oxide: Local signalling molecule produced by nerve cells and endothelial 
cells lining blood vessels. It causes smooth muscles to relax, causing blood 
vessel dilation, and regulates nerve cell activity. It is also produced by activated 
macrophages, neutrophils, and other cells. Nitric oxide produced by endothelial 
nitric oxide synthase (eNOS) has a vasodilator function and has atherogenic and 
vascular protective effects. However, nitric oxides produced by inducible nitric 
oxide synthase (iNOS) in macrophages appear to induce atherosclerosis. 
Ovariectomy: ovary removal: the surgical removal of one or both ovaries. 
Palpitations: Heartbeat sensations. Unpleasent awareness of your own heartbeat. 
You may feel that your heart is pounding or racing or you may fell skipped or 
stopped beats.  
Pharmacokinetics: (In Greek: "pharmacon" meaning drug and "kinetikos" 
meaning putting in motion, the study of time dependency) is a branch of 
pharmacology dedicated to the determination of the fate of substances 
administered externally to a living organism. 
Prophylactic: A preventive measure. The word comes from the Greek for "an 
advance guard," an apt term for a measure taken to fend off a disease or another 
unwanted consequence. 
Response element: Is a short sequence of DNA within the promoter of a gene that 
is able to bind a specific hormone receptor complex and therefore regulate 
transcription. 
Selective Estrogen Receptor Modulators (SERMs): Are a class of medication 
that acts on the estrogen receptor. A characteristic that distinguishes these 
substances from pure receptor agonists and antagonists is that their action is 
different in various tissues, thereby granting the possibility to selectively inhibit 
or stimulate estrogen-like action in various tissues. 
Thrombemolism: Formation in a blood vessel of a clot (thrombus) that breaks 
loose and is carried by the blood stream to plug another vessel. 
Transcription factor: A protein that binds to specific parts of DNA using DNA 
binding domains and is part of the system that controls the transfer (or 
transcription) of genetic information from DNA to RNA. 
Urogenital: The urogenital system includes the sex organs and the urinary system 
of vertebrates. 
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